Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to...
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical...
BOSTON, MA / ACCESSWIRE / August 15, 2023 / The VA Boston Healthcare System has implemented the Palarum® PUP® SmartSock...
SAINT GEORGE, UT / ACCESSWIRE / August 14, 2023 / Zion Healing Inc. and its subsidiary, Zion Healing Development Company,...
Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the...
Scientific Paper Presented at Research SymposiumJACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic...
Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for...
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key Findings Included Minimal Incidences of...
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients...
Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapiesHINGHAM, Mass., Aug....
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
POMPANO BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from...
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due...
Multi-site observational study seeks to redefine the standard of care for pediatric hydrocephalus managementGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the...
Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) (“RespireRx”), focused on the...
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
STOCKHOLM, SWEDEN / ACCESSWIRE / August 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in ChicagoChronic SCI cohort results expected in...